Summit Therapeutics to Host Third Quarter 2024 Financial Results & Operational Progress Call on October 30, 2024Business Wire • 10/23/24
Billionaire Israel Englander Just Quietly Took a Stake in This Potentially Lucrative Pharmaceutical Stock. Should You?The Motley Fool • 10/22/24
Better Biotech Stock to Buy With $1,500 Right Now: Viking Therapeutics vs. Summit TherapeuticsThe Motley Fool • 10/13/24
2 Soaring Stocks That Could Climb Another 112% and 120%, According to Wall Street AnalystsThe Motley Fool • 10/07/24
Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLCBusiness Wire • 10/03/24
This Stock Is Crushing Nvidia's Performance This Year: Is It Too Late to Buy?The Motley Fool • 09/22/24
Is It Too Late to Buy Summit Therapeutics Stock After Its Almost 10X Gain This Year?The Motley Fool • 09/19/24
This Company Generates No Revenue and Its Market Cap Is Over $20 Billion. Here's Why That Valuation May Not Be All That Ridiculous.The Motley Fool • 09/18/24
Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024Business Wire • 09/16/24